[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,296,901
  • Shares Outstanding, K 125,692
  • Annual Sales, $ 376,070 K
  • Annual Income, $ -16,140 K
  • EBIT $ 34 M
  • EBITDA $ 37 M
  • 60-Month Beta 1.49
  • Price/Sales 8.66
  • Price/Cash Flow N/A
  • Price/Book 14.70

Options Overview Details

View History
  • Implied Volatility 62.20% (+8.78%)
  • Historical Volatility 41.27%
  • IV Percentile 27%
  • IV Rank 24.30%
  • IV High 139.00% on 03/18/26
  • IV Low 37.55% on 07/17/26
  • Expected Move (DTE 9) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 77
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 10,142
  • Open Int (30-Day) 9,552
  • Expected Range 26.15 to 26.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $0.17
  • Number of Estimates 3
  • High Estimate $0.20
  • Low Estimate $0.15
  • Prior Year $0.06
  • Growth Rate Est. (year over year) +183.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.76 +5.94%
on 08/10/26
29.24 -10.29%
on 08/06/26
-1.51 (-5.44%)
since 07/10/26
3-Month
19.30 +35.94%
on 05/19/26
29.84 -12.10%
on 07/09/26
+5.54 (+26.78%)
since 05/12/26
52-Week
14.80 +77.23%
on 08/13/25
31.77 -17.44%
on 12/08/25
+11.49 (+77.95%)
since 08/12/25

Most Recent Stories

More News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 26.06 (-0.65%)
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Continued strong ZORYVE ® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand growth Company...

ARQT : 26.06 (-0.65%)
Arcutis Prepares to Defend ORYVE Expansion Amid Tightening Guidance

Barchart Research What to Expect from ARQT Earnings ARQT Generated August 4, 2026 Current Price $26.03 EPS Estimate $$0.09 Consensus Rating Moderate Buy Average Move 7.67% Arcutis Prepares to Defend ORYVE...

ARQT : 26.06 (-0.65%)
Arcutis Expands Board of Directors with Appointment of Chris Peetz

WESTLAKE VILLAGE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation...

ARQT : 26.06 (-0.65%)
Arcutis to Report Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

WESTLAKE VILLAGE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 26.06 (-0.65%)
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027 Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label...

ARQT : 26.06 (-0.65%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 26.06 (-0.65%)
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications

Virtual health platform offers an additional pathway to care for the more than 45 million people in the U.S. living with eczema, seborrheic dermatitis, and plaque psoriasis Connects eligible individuals...

ARQT : 26.06 (-0.65%)
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2

ZORYVE cream 0.3% is the first once-daily, non-steroidal therapy approved for children with plaque psoriasis as young as 2 years of age ZORYVE cream 0.3% is safe, effective, and well-tolerated for use...

ARQT : 26.06 (-0.65%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WESTLAKE VILLAGE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

ARQT : 26.06 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 27.76
2nd Resistance Point 27.29
1st Resistance Point 26.76
Last Price 26.06
1st Support Level 25.76
2nd Support Level 25.29
3rd Support Level 24.76

See More

52-Week High 31.77
Last Price 26.06
Fibonacci 61.8% 25.29
Fibonacci 50% 23.28
Fibonacci 38.2% 21.28
52-Week Low 14.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.